Results of Annual General Meeting held on 27 April 2017

Regulatory News Service

27 April 2017 17:30 BST


AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today.  As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 1 – 9 were passed as ordinary resolutions and resolutions 10 – 12 were passed as special resolutions.

 

RESOLUTION

VOTES FOR

% OF VOTES CAST

VOTES AGAINST

% OF VOTES CAST

VOTES CAST IN TOTAL

TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL

VOTES WITHHELD

1

To receive the Company’s Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2016

 

914,348,647

99.94

561,046

0.06

914,909,693

72.29

14,055,053

2

To confirm dividends

 

925,733,259

99.75

2,281,327

0.25

928,014,586

73.32

950,160

3

To appoint PricewaterhouseCoopers LLP as Auditor

 

925,181,852

99.71

2,679,401

0.29

927,861,253

73.31

1,103,493

4

To authorise the Directors to agree the remuneration of the Auditor

 

925,654,910

99.76

2,210,534

0.24

927,865,444

73.31

1,099,302

5a

To re-elect Leif Johansson as a Director

 

894,505,361

98.41

14,457,865

1.59

908,963,226

71.82

20,001,520

5b

To re-elect Pascal Soriot as a Director

 

923,508,459

99.55

4,220,473

0.45

927,728,932

73.30

1,235,814

5c

To re-elect Marc Dunoyer as a Director

 

913,734,060

98.52

13,766,446

1.48

927,500,506

73.28

1,464,240

5d

To re-elect Geneviève Berger as a Director

 

924,823,332

99.69

2,847,336

0.31

927,670,668

73.30

1,294,078

5e

To elect Philip Broadley as a Director

 

925,526,658

99.77

2,104,123

0.23

927,630,781

73.29

1,332,733

5f

To re-elect Bruce Burlington as a Director

 

924,643,428

99.68

2,996,388

0.32

927,639,816

73.29

1,324,930

5g

To re-elect Graham Chipchase as a Director

 

893,623,270

97.01

27,555,509

2.99

921,178,779

72.78

7,785,967

5h

To re-elect Rudy Markham as a Director

 

906,931,686

97.77

20,689,307

2.23

927,620,993

73.29

1,343,753

5i

To re-elect Shriti Vadera as a Director

 

921,267,292

99.31

6,370,592

0.69

927,637,884

73.29

1,326,862

5j

To re-elect Marcus Wallenberg as a Director

 

856,206,532

94.86

46,431,752

5.14

902,638,284

71.32

26,326,461

6

To approve the Annual Report on Remuneration for the year ended 31 December 2016

 

560,051,300

61.17

355,474,215

38.83

915,525,515

72.34

13,439,230

7

To approve the Directors’ Remuneration Policy

 

877,620,302

96.08

35,804,933

3.92

913,425,235

72.17

15,539,511

8

To authorise limited political donations

 

898,169,470

97.87

19,518,267

2.13

917,687,737

72.51

11,278,009

9

To authorise the Directors to allot shares

 

842,959,080

91.03

83,045,083

8.97

926,004,163

73.17

2,960,583

10

To authorise the Directors to disapply pre-emption rights

 

922,652,653

99.48

4,785,159

0.52

927,437,812

73.28

1,526,934

11

To authorise the Company to purchase its own shares

 

916,489,233

98.82

10,984,147

1.18

927,473,380

73.28

1,491,366

12

To reduce the notice period for general meetings

 

845,957,281

91.63

77,228,645

8.37

923,185,926

72.94

5,778,819


AstraZeneca is pleased to have achieved shareholder support for all resolutions proposed at the AGM. AstraZeneca received a 96.08% binding vote approving the Remuneration Policy and a 61.17% advisory vote in favour of its Annual Report on Remuneration for the year ended 31 December 2016.

AstraZeneca engaged extensively with its major shareholders on remuneration matters during 2016 and the Remuneration Committee’s proposals were based on shareholder feedback. AstraZeneca notes that its major shareholders exercised their independent judgement following this consultation, with the majority of them voting in favour of the Remuneration Report. The lower level of support for the Remuneration Report is considered to reflect concerns regarding how the AstraZeneca Investment Plan (AZIP) will be operated for the outstanding AZIP awards previously made, and the level of information given about the annual bonus plan and awards. AstraZeneca’s Remuneration Committee will continue the dialogue with shareholders, as appropriate, regarding any concerns following its AGM.

Issued capital
As at 25 April 2017, the number of issued shares of the Company was 1,265,630,929 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM.  In accordance with the Company’s Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.


CONTACTS

Media Enquiries

 

 

 

 

Esra Erkal-Paler

UK/Global

+44 203 749 5638

Vanessa Rhodes

UK/Global

+44 203 749 5736

Karen Birmingham

UK/Global

+44 203 749 5634

Rob Skelding

UK/Global

+44 203 749 5821

Jacob Lund

Sweden

+46 8 553 260 20

Michele Meixell

US

+1 302 885 2677

 

 

 

 

Investor Relations

 

 

Thomas Kudsk Larsen

 

+44 203 749 5712

Craig Marks

Finance, Fixed Income, M&A

+44 7881 615 764

Henry Wheeler

Oncology

+44 203 749 5797

Mitchell Chan

Oncology

+1 240 477 3771

Lindsey Trickett

Cardiovascular & Metabolic Diseases

+1 240 543 7970

Nick Stone

Respiratory

+44 203 749 5716

Christer Gruvris

Autoimmunity, neuroscience & infection

+44 203 749 5711

US Toll-Free

 

+1 866 381 7277

 

Adrian Kemp

Company Secretary, AstraZeneca PLC

tags

  • Regulatory